Back to Search Start Over

Essential thrombocythaemia.

Authors :
Barranco-Lampón G
Martínez-Castro R
Arana-Luna L
Álvarez-Vera JL
Rojas-Castillejos F
Peñaloza-Ramírez R
Carballo-Zarate AA
Olarte-Carrillo I
Minamy JI
López-Salazar J
Navarrete JJ
Espinosa-Partida A
Ventura-Enríquez Y
Ruiz-Contreras JI
Aguirre-Reyes OG
Anaya-Cuéllar I
Aguilar-Luévano J
Díaz-Ramírez HF
Herrera-Olivares W
Aguilar-Hidalgo JA
Alcívar-Cedeño LM
Hernández-Caballero Á
Galaz-Cordero LE
Peña-Celaya JA
Báez-Islas PE
Bates-Martín RA
Cano-León AML
Espitia-Ríos ME
Barbosa D
Morales-Adrián J
Pacheco MJ
Delgado-López N
Neme-Yunes Y
Moralws-Hernández AE
Mújica-Martínez A
Pérez-Lizardi AB
Pérez-Gómez KD
Barragán-Ibáñez G
Martínez A
Flores-Ordúñez K
Ramírez-Hoyos P
Ángeles Rosales-López ML
Acosta-Maldonado BL
Jiménez-Ochoa MA
Garzón-Velásquez KB
Hernández-Ruiz E
McNally-Guillén BM
Saucedo-Montes EE
Aguilar-Andrade C
Vivas-Arteaga CL
Guerra-Alarcón LV
Milán-Salvatierra AI
Campa-Monroy DI
Cota-Rangel X
Estrada-Domínguez P
García-Camacho AS
García-Castillo C
Banda-García LI
Rodríguez-Sánchez V
Meillón-García LA
Urbina-Escalante E
Martínez-Ramírez MA
Loera-Fragoso SJ
Martínez-Coronel J
Zapata-Canto N
Gómez-Cortés SC
Medina-Coral JE
Mójica-Balderas L
Pérez-Zúñiga JM
Pérez FJ
López-Arroyo JL
Zazueta-Pozos JF
Romero-Martínez E
Romero-Rodelo H
Tapia-Enríquez AL
Soriano-Mercedes EJ
Salazar-Ramírez Ó
Vilchis-González SP
Tepepa-Flores F
Alvarado-Ibarra M
Source :
Gaceta medica de Mexico [Gac Med Mex] 2022; Vol. 158 (Supl 1), pp. 17-25.
Publication Year :
2022

Abstract

Essential thrombocythemia (ET) is a chronic Philadelphia-negative myeloproliferative neoplasm that has its main involvement in the megakaryopoietic lineage, generating sustained thrombocytosis in peripheral blood and an increase in the number of mature megakaryocytes in the bone marrow. In addition to marked thrombocytosis, it is characterized by increased thrombotic or hemorrhagic risk and the presence of constitutional symptoms. Patients with ET have a low but known risk of disease progression to myelofibrosis and/or acute leukemia. The diagnosis is made based on the 2016 WHO criteria. At present, available treatments for patients with ET are mainly aimed at minimizing the risk of thrombosis and/or bleeding.<br /> (Copyright: © 2022 Permanyer.)

Details

Language :
English
ISSN :
0016-3813
Volume :
158
Issue :
Supl 1
Database :
MEDLINE
Journal :
Gaceta medica de Mexico
Publication Type :
Academic Journal
Accession number :
37734042
Full Text :
https://doi.org/10.24875/GMM.M22000803